Notable’s Post

Excited to have attended an insightful symposium on Drug Delivery Systems, where I had the opportunity to dive deep into advanced topics such as Natural cell-derived delivery, exosomes, ophthalmic suspensions, cancer therapeutics, pharmacokinetic modeling, and complex injectables. It was a privilege to learn from leading experts in the field like Dr. Mandeep Singh Sachdeva and Dr. Birendra Kumar, who shared groundbreaking research and developments. These discussions have broadened my understanding of innovative drug delivery mechanisms and their potential to transform patient care. Looking forward to applying these insights as I continue my journey in Pharmaceutics! #DrugDelivery #Pharmaceutics #CancerTherapeutics #Pharmacokinetics #Exosomes #OphthalmicSuspension #ComplexInjectables #Learning

🔬 Understanding the critical role of MOA Modelling in drug development 💡 Mechanism of Action (MOA) modelling goes beyond traditional pharmacokinetics (PK) and pharmacodynamics (PD) approaches by incorporating additional biological components, which enhances the understanding of a drug's effects. At Physiomics, we have extensive experience in MOA modelling, with most of our models including these crucial mechanistic components. Our expertise in mechanistic and semi-mechanistic PK/PD modelling can help: 👉 Facilitate discussions with investors and regulators by providing robust evidence of how your drug works. 👉 Identify potential drug combinations that may work synergistically, enhancing therapeutic effects. 👉 Suggest confirmatory studies to validate your drug's mechanisms and support its development. Curious to learn more? Check out how we can help de-risk your R&D process with our advanced modelling techniques! https://buff.ly/4atVfGg #DrugDevelopment #Biotech #Pharma #Cancer #CancerDrugs #CancerSimulation #CombinationTherapies #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #StatisticalModelling #MachineLearning #TranslationalModelling #PYC

Our (www.accelerobio.com) Oral presentation on “Speeding up drug discovery with high-quality and high-reliability crystallography-based library screening” at the 74th annual meeting of the American Crystallographic Association conference in Denver next week, including an emphasis on how this approach has resulted in hits and rapid advancement to leads against the undruggable DDR endonuclease APE1 showing promise in cellular assays of glioblastoma and ovarian and breast cancers at our partner XPose Therapeutics. Key: simultaneous discovery and production of hits, co-crystal structures, novel sites, allosteric sites, targeting undruggables, for small molecule modulators and targeted protein degradation, by our protein X-ray crystallography-driven drug discovery and feeding into our Analytics/ML/AIDD (AI Drug Discovery). #drugdiscovery #therapeutics #oncology #structuralbiology

SFBN Feed: Unpacking IRA price negotiations results; Lykos’ tough week; Genentech rethinks cancer immunology; and more https://lnkd.in/gcm3Entw Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Peptides in Radiopharmaceutical: A New Era in Cancer Treatment and Personalized Medicine. . . . Peptides are revolutionizing the world of cancer treatment, offering better tissue penetration, reduced toxicity, and more targeted therapies.  . . . As the demand for personalized medicine grows, companies like WuXi AppTec are expanding peptide manufacturing to meet the rising global need. From advanced cancer therapies to broader medical applications, peptides are at the forefront of transformative changes in modern healthcare. . . . 💡 Curious about how peptides are changing the medical landscape? Click the link here to read the full article about the potential for peptides to replace antibodies in radiopharma. https://lnkd.in/gKXvmTwM . . . #Pharmlabs #Peptides #Radiopharmaceutical #CancerTreatment #PersonalizedMedicine #TargetedTherapies #MedicalInnovation #HealthBreakthrough #PeptideTherapy #PharmaceuticalTechnology #WuXiAppTec #CancerResearch #Biotechnology #PeptideScience #MedicalAdvances #HealthTech #TherapeuticInnovation #FutureOfMedicine #HealthcareInnovation #BioTechIndustry #PeptideTherapeutics

💥Accelerate Your Drug Development with Clinically Relevant B-ALL Models 💥Champions' industry leading Systemic B-ALL In Vivo Screen is now enrolling until January 31st. Enroll now: https://hubs.li/Q02-sVXV0 Our team of experts source rare and clinically relevant B-ALL models that retain key clinical characteristics and replicate the clinical outcomes and heterogeneity observed in patients—making them ideal for testing new B-ALL therapeutics. #BALL #DrugDevelopment #Oncology #ResearchModels #TherapeuticScreening #CancerResearch #Hematology #PatientDerivedXenografts #PDX #preClinicalResearch #Innovation #Biotech #ChampionsOncology #BCellAcuteLymphoblasticLeukemia #hemeonc

The Cerbrec team had a great conference experience at the MarketsandMarkets™ Next-Gen #Immuno-Oncology Conference! We had productive discussions with research scientists from #biotech and #pharma companies, ranging from #startups to #Fortune500 corporations. Many are looking to collaborate and start trials to expedite drug discovery with AI by 8-10 times with our graphical and intelligent deep learning framework. A huge thank you to the #MarketsandMarkets team and everyone who visited our booth for an unforgettable experience. We're excited to apply the insights and connections made to drive meaningful change for #biotech and #pharma companies. Send us an inquiry or book a demo by reaching us at info@cerbrec.com to explore how Cerbrec can help your research and development efforts. #Oncology #Oncologyresearch #Cancer #Medicine #Oncologia #Immunooncology #Healthcare #Therapy #Pharmaceutical #Marketsandmarkets #SafeAI #ResponsibleAI #AiSecurity #AiAdoption #GenAI #Cerbrec

On top of its impact in preclinical research, PEDRA can also be used to assess therapy resistance in clinical studies. So, if this is your topic it might be worth to also take a closer look ;).

We'll be hosting a webinar related to the discovery and development of Antibody Drug Conjugates on Friday, Septmeber 13th from 10-10:30am PST. Don't be scared away by the date! REGISTER NOW: https://lnkd.in/gs2ti4k4 Topics covered: -Selection and optimization of immunoassays from relevant preclinical tumor models using ADCs -Pharmacokinetics, Pharmacodynamics, and Immunogenicity considerations using an open MSD platform for any ADC -Potential safety and efficacy biomarkers to port to the open MSD platform #antibodydrugconjugates #immunooncology #immunoassays #ADCs #biomarkers #bioanalysis

Latest DON Healthcare news First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer Adaptimmune’s Tecelra is the first TCR cell therapy to reach the U.S. market, but arrives with only modest sales expectations. The Food and Drug Administration on Thursday approved a new type of cellular medicine, clearing a therapy developed by the biotechnology company Adaptimmune for a rare soft tissue cancer called synovial sarcoma. The agency granted Adaptimmune’s therapy, formerly known as afami-cel and to be sold as Tecelra, an accelerated approval for use in some people with metastatic synovial sarcoma who previously received chemotherapy. Those people must have certain immune signatures and tumors expressing a protein, MAGE-A4, that Tecelra is designed to target. We are always looking for new possibilities in healthcare. If you are a decision-maker, submit your opportunity via this link: https://lnkd.in/eQcjSSWk Help us build a network that can make a real difference to people's health. Join our FREE Healthcare platform today - www.don-healthcare.com #Innovation #BioTech #CancerResearch #FutureofMedicine